London, UK (PRWEB) June 08, 2015
The duchenne muscular dystrophy (DMD) and becker muscular dystrophy (BMD) pipeline is populated by 84 molecules across all development stages. This indication hass witnessed a high level of innovation and diversity; 70% of the products in the pipeline are first-in-class ones, which act on 13 first-in-class targets.
This exceptional first-in-class innovation mainly stems from the large number of first-in-class products exceptionally targeting the human dystrophin gene, which is the chiefly genetic cause of BMD and DMD. The strong presence of first-in-class products in the pipeline creates a distinctly various landscape to the market space, relying on symptomatic treatment with glucocorticoids (GCs). Notwithstanding Translarna (ataluren) having been developed to correct the inherent genetic disorders, considerable unmet needs still exist in the marketplace, as the therapy is applicable to just 10–15% of all DMD cases resulting from nonsense mutations.
In spite of a strong focus on personalised therapies treating the genetic cause of the indication in the DMD and/or BMD pipeline, innovation is also focused on novel molecular targets that alleviate the development of dystrophic pathology without regard to gene mutations, hence allowing extensive use versus the mutation specific treatments. These therapies are expected to be utilised along with primary treatment to restore the mutated gene, stop muscle degeneration, and enhance patients’ life expectancy in the market moving forward.
Topical research report “Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research is now available at MarketPublishers.com.
Title: Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
Published: May, 2015
Price: US$ 6,995.00
The research report limelights the innovation in DMD and/or BMD with respect to the overall pipeline and present market landscape. Additionally, it presents an all-encompassing guide to the deals landscape embracing first-in-class products in DMD/BMD and identifies a slew of lucrative opportunities for in-licensing.
- Review of DMD/BMD, comprising pathophysiology, symptoms, and an look at pharmacologic therapy and treatment algorithms.
- Examination of the dynamic molecular target landscape between pipeline and market and specific focal points of innovation in the pipeline.
- All-round coverage of the first-in-class therapies pipeline, analysed based on development phase, type of molecule, and molecular target.
- Granular analysis of first-in-class molecular targets, with emphasis on early-stage programmes for which clinical utility is to be assessed, as well as overviews of new molecular targets.
- Insights into the co-development and licensing deals landscape for DMD/BMD treatment options along with benchmarking of deals that involve non-first-in-class versus first-in-class products.
More studies by the publisher can be found at GBI Research page.